EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieMultizentrische StudieOpen Access · CC BY 4.0

Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial

Pekka Raatikainen iD, Heikki Mäkynen iD, Juha Hartikainen iD, Mats Jensen Urstad iD, Leena Konkola, Niels C F Sandgaard iD, Peter Lukac iD, Arne Johannessen iD, Anders Jönsson, Peter Schuster iD, Carina Blomström-Lundqvist iD, Jussi Kuutti iD und 2 weitere

Europace · 2025

DOI: 10.1093/europace/euaf236 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Europace, 2025. Verfasst von Pekka Raatikainen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, Helsinki 00290, Finland. Hauptthemen laut MEDLINE: Tachycardia, Ventricular, Anti-Arrhythmia Agents, Catheter Ablation, Myocardial Infarction. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biosense Webster Inc, Cardiovascular Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Ventricular tachyarrhythmias (VT/VF) are common among patients with prior myocardial infarction (MI). MANTRA-VT trial was designed to compare the efficacy and safety of early substrate-based radiofrequency catheter ablation (RFCA) to antiarrhythmic drug (AAD) therapy for ventricular tachyarrhythmias. Methods and results We randomly assigned 58 AAD naïve post MI patients with implantable cardioverter defibrillator (ICD) and at least one documented VT/VF episode after the device implantation to an initial treatment strategy of substrate-based RFCA or AAD therapy. The primary endpoint was cumulative number of ventricular tachyarrhythmias (VT/VF burden) at 12 months. The secondary endpoints included all-cause mortality, hospitalization, adverse events, and VT/VF burden at 24 months. Analyses were performed on an intention-to-treat basis. The median number of VT/VF episodes at 12 months was zero in both the RFCA (range 0–3) and the AAD group (range 0–23) (P = 0.454), whereas the rate of appropriate ICD shocks was 7% and 30% in the RFCA and the AAD groups (P = 0.026), respectively. During the extended follow-up, 82% of the patients in the RFCA group and 63% in the AAD group had no ICD therapies (P = 0.012). There was no significant difference between the groups in total mortality (HR 1.02, 95% CI 0.20–5.11, P = 0.86) and hospitalization (HR 1.35, 95% CI 0.36–5.09. P = 0.66) at 24 months. Therapy-related adverse events occurred in 3.6% and 16.7% of the patients in the RFCA and the AAD groups (P = 0.10), respectively.

Conclusion

Early substrate-based RFCA was associated with reduced risk of ICD therapies, but with no meaningful difference in VT/VF burden, mortality, hospitalization, and adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tachycardia, VentricularAnti-Arrhythmia AgentsCatheter AblationMyocardial InfarctionVentricular FibrillationHumansMaleFemaleMiddle AgedAgedDefibrillators, ImplantableTreatment OutcomeHospitalizationTime Factors

Stichwörter der Autor:innen

Antiarrhythmic drug therapyICD therapyMyocardial infarctionRadiofrequency catheter ablationRandomized trialVentricular tachyarrhythmia

Substanzen

Anti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Cardiology, Heart and Lung Center, Helsinki University Hospital and University of Helsinki, Haartmaninkatu 4, Helsinki 00290, Finland.
  • Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä, Finland.
  • Heart Hospital Tampere University Hospital, Tampere, Finland.
  • Heart Center, Kuopio University Hospital, Kuopio, Finland.
  • University of Eastern Finland, Kuopio, Finland.
  • Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.

ORCID-Profile: Pekka Raatikainen, Heikki Mäkynen, Juha Hartikainen, Mats Jensen Urstad, Niels C F Sandgaard, Peter Lukac, Arne Johannessen, Peter Schuster, Carina Blomström-Lundqvist, Jussi Kuutti, Piia Lavikainen

Förderung

  • Biosense Webster Inc
  • Cardiovascular Research

Zitieren

APA

Raatikainen, P., Mäkynen, H., Hartikainen, J., Urstad, M. J., Konkola, L., Sandgaard, N. C. F., Lukac, P., Johannessen, A., Jönsson, A., Schuster, P., Blomström-Lundqvist, C., Kuutti, J., Lavikainen, P., & Parikka, H. (2025). Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial. Europace. https://doi.org/10.1093/europace/euaf236

Vancouver

Raatikainen P, Mäkynen H, Hartikainen J, Urstad MJ, Konkola L, Sandgaard NCF, et al. Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial. Europace. 2025. doi:10.1093/europace/euaf236

BibTeX
@article{Raatikainen2025,
  author = {Raatikainen, Pekka and Mäkynen, Heikki and Hartikainen, Juha and Urstad, Mats Jensen and Konkola, Leena and Sandgaard, Niels C F and Lukac, Peter and Johannessen, Arne and Jönsson, Anders and Schuster, Peter and Blomström-Lundqvist, Carina and Kuutti, Jussi and Lavikainen, Piia and Parikka, Hannu},
  title = {Early substrate-based catheter ablation vs. antiarrhythmic drug therapy for ventricular tachyarrhythmias among patients with prior myocardial infarction: the MANTRA-VT randomized trial},
  journal = {Europace},
  year = {2025},
  doi = {10.1093/europace/euaf236}
}
Kostenlos starten →